Abbreviations used in this paper: EBRT = external-beam radiation therapy; GTR = gross-total resection; KPS = Karnofsky Performance Scale; NS = not significant; NTR = near-total resection; SRS = stereotactic radiosurgery; UCSF = University of California at San Francisco.
A ccording to the WHO in 2007, 90% of meningiomas are classified as benign, 5-7% as atypical, and 1-3% as malignant.
14 There are numerous case studies in the literature addressing the issue of benign and atypical meningiomas from a surgical standpoint, including case series examining several hundred patients. 1, 12 However, strikingly little data exists regarding the clinical behavior of malignant meningiomas. The largest retrospective study previous to this one included 22 patients. 2 Despite increasing understanding of the histological and molecular markers of tumor progression in malignant meningiomas, 2, 3, 5, 17 there is a paucity of published clinical data on this grade of lesion. Even less is known about the appropriate course of action in the setting of recurrent tumor. [6] [7] [8] Following repeat operation for recurrence, adjuvant treatments including radiosurgery, chemotherapy, and brachytherapy have been tried with limited success in this patient population.
We present the largest case series to date dealing with malignant meningiomas, providing analysis of 63 patients. From this large cohort, we provide data regarding expected outcomes and surgical risk, and draw some preliminary conclusions regarding appropriate surgical management strategies.
Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas 
Brain Tumor Research Center, Department of Neurological Surgery, University of California at San Francisco, California
Object. Despite an increased understanding of the biology of malignant meningioma tumor progression, there is a paucity of published clinical data on factors affecting outcomes following treatment for these lesions. The authors present the largest case series to date dealing with these tumors, providing analysis of 63 patients.
Methods. The authors identified all patients undergoing resection of WHO Grade III tumors at their institution over a 16-year period. They analyzed clinical data from these patients, and performed Kaplan-Meier and Cox regression analyses to determine the impact of different clinical characteristics and different treatment modalities on survival following initial and repeat surgery for these lesions.
Results. Sixty-three patients met inclusion criteria and were analyzed further. The median clinical follow-up time was 5 years (range 1-22 years). The 2-, 5-, and 10-year overall survival rates following initial operation were 82, 61, and 40%, respectively. Kaplan-Meier analysis demonstrated a marked survival benefit with repeat operation (53 vs 25 months, p = 0.02). Interestingly, patients treated with near-total resection experienced improved overall survival when compared with patients treated with gross-total resection at initial (p = 0.035) and repeat operations (p = 0.005). Twelve (19%) of 63 patients experienced significant neurological morbidity referable to the resection of their tumors.
Conclusions. Surgery is an effective treatment for WHO Grade III meningiomas at presentation and recurrence; however, aggressive attempts to achieve gross-total resection can be associated with significant neurological risk. 
Methods

Patient Population
All patients undergoing neurosurgical intervention at UCSF are prospectively enrolled in a database. Using this database, we identified 1228 patients with meningioma for which some data were available. From this cohort, we selected patients with a final histopathological finding of anaplastic or malignant meningioma for further analysis. Because the goal of this study was to analyze the clinical behavior of de novo malignant meningiomas, we excluded all patients with potentially confounding neurosurgical histories. For example, we excluded from further analysis patients with additional or prior intracranial tumors other than Grade III meningiomas as well as all patients who had undergone intracranial radiation for reasons other than their malignant meningioma. This study was approved by the UCSF Committee on Human Research under the approval number H7828-29842-03.
Microsurgical Technique and Perioperative Management
Preoperative evaluation of all patients included T1-and T2-weighted MR imaging with and without contrast. Use of contrast allows visualization of the extent of tumor, whereas T2 images may display the arachnoid layer around the tumor and adjacent brain edema, the latter giving some indication of adhesion to the surrounding parenchyma. Preoperative embolization was performed for larger tumors based on the discretion of the treating surgeon, and when the supplying vessels were accessible for intravascular occlusion with polyvinyl alcohol particles. The goal of preoperative embolization was to reduce both tumor vascularity and intraoperative blood loss, consistent with our prior published experience. 9 Surgery was only performed after induction of general anesthesia and with endotracheal intubation. All surgeries performed after 1993 benefitted from the use of surgical navigation systems of a variety of types and manufacturers, whereas those performed prior to that date relied on the use of a larger craniotomy, as was the standard for that time. Standard microsurgical techniques were used. Due to the infiltrative nature of anaplastic lesions, the pial plane was usually obliterated throughout the tumor-parenchymal interface. These tumors tend to be softer in composition than benign meningioma types, and therefore are usually debulked using the Cavitron ultrasonic surgical aspirator (Integra Neuroscience) and/or the Sonopet (Miwatec). On completion of the tumor debulking and/or removal, the bone flap was replaced and the scalp reapproximated. Tumor-involved bone was removed, and cranioplasty was done with titanium mesh and/or methylmethacrylate.
Intraoperatively, all patients received decadron (10 mg), mannitol (1 g/kg), and ceftriaxone (1 or 2 g) at the time of incision. Postoperatively, all patients were cared for in a neurointensive care unit for 1 day before returning to the ward. On postoperative Day 2, a prophylactic dose of enoxaparin (40 mg subcutaneously each day) was initiated in most patients and continued for 1 week. Routine use of venous thrombosis prophylaxis was not started until after 2001. The incidence of postoperative intracranial hemorrhage was no different in the patient groups before or after prophylaxis was initiated. 4 Regardless of preoperative seizure history, all patients also received loading doses of an antiepileptic agent at the time of surgery (Dilantin initially, Keppra more recently), which was continued for 1 week postoperatively and was then discontinued, following guidelines for patients with severe traumatic brain injury.
Postoperatively, all patients underwent fractionated EBRT following their initial operations. At the discretion of the treating surgeon and radiation oncologist, some patients undergoing surgery for recurrent tumors had permanent 125 I brachytherapy seeds implanted at the time of their repeat surgery. Additionally, following the second surgery, small focal recurrences were frequently treated with 1 or more sessions of SRS and/or a repeat resection at the discretion of the treating surgeon and radiation oncologist.
Data Collection
Clinical information was retrospectively reconstructed using patients' medical records, radiological data, and pathological specimens from both UCSF and the other medical facilities. All clinical assessments were performed by a neurosurgeon, and whenever necessary, the attending surgeon was consulted to clarify any discrepancies. The preoperative, postcontrast T1-weighted MR imaging studies were reviewed to confirm tumor location, such as convexity dura mater, skull base, tentorium, falx, or intraventricular. Tumors that were multifocal were classified according to which portion of the tumor was largest and the location of its primary attachment. Central pathology review was performed on the basis of the 2000 WHO guidelines.
In each case, the extent of resection was analyzed based on both a subjective surgical impression of NTR versus GTR, and by using the Simpson grading scale. This information was obtained from the surgeon's assessment found in the operative notes. In all cases, the MR imaging correlated with the surgeon's intraoperative impression. Importantly, we approached each case with the plan of attempting total tumor removal, and at most only small amounts of tumor were left, in a conscious effort to preserve the integrity of vital neural and vascular structures.
Assessment of the patients' KPS values was done using clinic records of pre-and postoperative visits. Mortality data were determined from medical records, and were cross-checked against the Social Security Death Index. All data were compiled in an electronic database and crosschecked for accuracy before being subject to any statistical analysis.
Statistical Analysis
Survival and progression analysis was performed using Kaplan-Meier analysis, with between-group differences being analyzed using the log-rank test. Statistically significant between-group differences were subsequently analyzed using Cox regression analysis, in which the covariates of age and KPS score, which we hypothesized might be potential confounders, were forced into the regression model to ensure that the apparent between-group differences were not falsely created by confounding variables. Cox regression analysis included comparisons of outcomes for patients undergoing both primary surgery and second surgery for recurrence at UCSF, with between-group survival comparisons being performed using the Kendall tau test.
We also tested interaction terms between each of the variables with age and KPS. The statistical significance of the interactions was assessed using backward conditional stepwise regression, in which statistical significance was estimated by means of the likelihood-ratio test to assess the effect of removing interaction terms for all strata of the given variable.
11 After finding that none of the interaction terms would significantly alter the log likelihood of the regression model if removed (unadjusted p > 0.2 for all terms), we calculated the adjusted hazard ratios without adjusting for interactions. In all cases studied, the inclusion or exclusion of age and/or KPS score did not meaningfully alter the proportional hazard ratio for variables displaying significant differences in the KaplanMeier analysis. Taken together, these data suggest that the between-group survival data do not represent an epiphenomenon resulting from between-group differences in the confounder categories of age or KPS score, and therefore, univariate data resulting from Kaplan-Meier analysis is presented in this study.
For the patients who underwent primary surgery at another hospital and second surgery at UCSF, these individuals were only included in the second surgery analysis because adequate clinical information was usually not available for their primary surgery. Additional subgroup comparisons included analyses of the effects of extent of resection and tumor location on survival outcomes after both primary and second surgery.
Continuous variables were compared using an independent-samples t-test after statistical tests demonstrated a gaussian distribution of the data. Continuous data were expressed as the mean ± SE. Between-group comparisons of binary variables was done using the chi-square test. Significance was defined at p < 0.05. All descriptive and statistical analysis was performed using SPSS version 15.0 statistical software.
Results
Patient Demographics
Data were available for 1228 patients with meninigioma evaluated at our institution over a 22-year period. A Grade III meningioma was identified in a total of 80 (6%) of these patients. Of these, 63 met inclusion criteria and were analyzed further. The demographic characteristics of these patients can be seen in Tables 1-3 . The median age at presentation was 51 years (range 2-89 years). Thirty-eight patients (60%) were female and 25 (40%) were male. Most patients presented with signs and symptoms attributable to mass effect at the tumor site, including hemiparesis (16%), headache (14%), and seizure (8%). Twenty-one patients (33%) were asymptomatic, but serial MR imaging demonstrated growth of > 2 mm in a single calendar year. The mean KPS score for patients undergoing initial surgery at UCSF was 72 ± 2.3, and the mean KPS score at the time of the second surgery was 64 ± 2.3.
Twenty-nine patients (46%) were initially treated by microsurgical dissection and postoperative radiotherapy at other facilities, and their second surgery for recurrence was performed at UCSF. Thirty-four patients had their initial treatment at UCSF (54%). Thirty-nine patients had tumors primarily of the convexity dura mater (62%), 11 lesions were skull base tumors (17%), 5 were tumors of the falx (8%), 5 were of the tentorium (8%), and 3 were intraventricular (5%). Sixteen patients (25%) underwent preoperative embolization, with the most commonly embolized vessels being the middle meningeal and superficial temporal arteries. As shown in Table 3 , Simpson Grade 0 or 1 resection was achieved in 13 patients (21%), a Simpson Grade 2 was achieved in 12 patients (19%), Simpson Grade 3 in 15 patients (24%), and 23 were Simpson Grade 4 (37%).
The median clinical follow-up time was 5 years (range 1-22 years). All patients received postoperative radiotherapy after their primary surgery. The 125 I brachytherapy was administered to some patients at the time of the second surgery, at the discretion of the treating surgeon. Some patients with recurrence instead received Gamma Knife surgery at the discretion of the treating surgeon, in consultation with the radiation oncologists. In any case, a smaller extent of resection was attributed to conscious attempts by the operating surgeon to reduce the risk of patient morbidity, because many of these tumors had either 
Outcome After Initial Resection of Malignant Meningiomas
Of the 34 patients who underwent primary surgery at UCSF, 16 (47%) had known radiographic recurrence during a mean follow-up period of 6.9 ± 1 years, for a total of 45 patients (16 first treated at UCSF and 29 at other hospitals) in the recurrent meningioma cohort. All patients with primary surgery performed at UCSF and with a diagnosis of malignant meningioma were referred for postoperative high-dose EBRT. A total of 22 patients died during the follow-up period. Of these, 6 were lost to follow-up, but were known to have died based on death records. Twelve patients were alive and known to be recurrence-free at the latest follow-up.
The 30-day perioperative mortality rate was 1 (3%) of 34. The 2-, 5-, and 10-year recurrence-free survival after primary surgery at UCSF was 80, 57, and 40%, respectively. The 2-, 5-, and 10-year overall survival for this group was 82, 61, and 40%. A Kaplan-Meier curve depicting the overall survival of this group is depicted in Fig.  1 upper.
Outcome After Repeat Resection of Malignant Meningiomas
A total of 45 patients were evaluated at UCSF for recurrent malignant meningioma. Of these, 37 patients elected to undergo a second operation, and 8 did not. Patients not undergoing a second surgery displayed a statistical trend toward older age at time of recurrence (60 ± 6.4 vs 45 ± 2.9 years; p = 0.12, t-test). The KPS score did not differ significantly between groups at the time of recurrence (70 ± 4.2 vs 58 ± 3.3; NS, t-test). Kaplan-Meier analysis demonstrated a marked survival benefit with repeat operation (p = 0.02, log-rank test) (Fig. 1 lower) . The median survival after repeat surgery was 53 months, compared with 25 months in those who did not undergo surgery at the time of first recurrence. Factors associated with the decision whether to operate were not uniformly available, and when provided often included nonmedical/ nonsurgical reasons (that is, patient preference to avoid more surgery).
Impact of Extent of Resection on Survival After Surgery for Malignant Meningiomas
Of the 34 patients undergoing primary surgery at UCSF, a GTR was obtained in 23 cases, with an NTR obtained in 11 cases. Interestingly, patients treated with NTR and EBRT at initial surgery experienced improved overall survival when compared with patients treated with GTR and radiotherapy (p = 0.035, log-rank test). The median survival with NTR was 107 months, compared with 50 months for GTR (Fig. 2 upper) . Despite the fact that there was no difference in KPS score in patients undergoing NTR versus GTR prior to the first operation (71.3 ± 2.8 vs 72.7 ± 4.1; NS, t-test), the fraction of patients with a postoperative KPS score of < 70 was greater in the GTR than in the NTR group (52 vs 27%), raising the possibility that GTR affected functional status in this cohort, and this may have influenced the risk of medical complications, and, as a result, decisions on additional treatment. Notably, no difference in time from surgery to initiation of radiation therapy was seen between Fig. 1 . Upper: Kaplan-Meier curves depicting the overall survival of the 34 patients undergoing primary surgery at UCSF. Lower: KaplanMeier curves depicting a marked survival benefit for the 37 patients undergoing a second operation. A Cox regression analysis controlling for age and KPS score also demonstrated a benefit for repeat surgery (p = 0.02).
the NTR and GTR groups (NS, chi-square test), suggesting that this difference was not due to the patients with NTR undergoing earlier radiation due to concerns regarding residual disease.
A similar relationship was seen for patients undergoing their second surgery at UCSF. Patients undergoing NTR lived significantly longer following their second surgery than did those undergoing GTR (median survival 77 vs 42 months; p = 0.005, log-rank test; Fig. 2 lower) . Additionally, there were no between-group (NTR vs GTR) differences between the proportion of patients (NS, chi-square test) who eventually received additional postoperative focal radiotherapy (either SRS or intercavitary brachytherapy), suggesting that the differences between groups cannot be explained by additional treatment being given to patients with residual disease.
Impact of Tumor Location on Survival After Surgery for Malignant Meningiomas
Of the 63 patients included in this series, 39 presented with convexity-based tumors, 5 had tumors based at the falx, and 11 lesions originated from the skull base. In addition, 3 patients had intraventricular lesions, and in 5 the tumors originated from the tentorium. Although the median survival of patients with convexity meningiomas (116 months) was marginally greater than that for patients with falcine (88 months) and skull base (105 months) tumors, none of these differences was statistically significant.
Impact of Additional Focal Radiotherapy on Survival Following Second Surgery
Twenty-six (58%) of 45 patients undergoing resection of a recurrent malignant meningioma eventually underwent at least 1 treatment with focal radiotherapy-either 1 or more treatments with SRS (13 patients) or permanent 125 I brachytherapy implants (13 patients). These treatments occurred either during the second surgery, immediately following it, or at the time of the second recurrence. Survival analysis found no difference in postoperative survival between patients receiving focal radiotherapy and those receiving no additional radiotherapy (NS, log-rank test). Additional subgroup analyses demonstrated that neither SRS (NS, log-rank test), nor brachytherapy (NS, log-rank test), appreciably improved survival after the second surgery.
Morbidity and Mortality Related to Resection of Malignant Meningiomas
The rate of perioperative death within 30 days of surgery was 2% (1 of 63). This patient had a convexity meningioma and died on postoperative Day 15 of a basilar artery stroke.
Nearly half (41%) of patients experienced at least 1 medical, surgical, or neurological complication following their surgery. There were no known intraoperative complications in our series, such as a direct major vessel or nerve injury. The overall rate of medical complications, such as deep venous thrombosis and/or pulmonary embolus, cardiac complications, and pneumonia was 6 (10%) of 63. There was no difference between rates of medical complications for patients undergoing primary or second surgery, or between rates for patients receiving a GTR or an NTR (NS, chi-square test; Table 4 ).
The overall rate of neurosurgical complications, such as CSF leaks, wound complications, and hydrocephalus, was 13 (21%) of 63. There was no difference between rates of surgical complications for patients undergoing primary or second surgery, or between rates for patients receiving a GTR or an NTR (NS, chi-square test; Table 4 ).
Twelve (19%) of 63 patients experienced significant neurological morbidity referable to the resection of their tumors. Because almost all of these tumors had transgressed the pial boundary into the brain, much of the transient neurological morbidity was thought to be directly related to this surgical trauma. These complications are summarized in Table 5 . The rate of serious neurological complications was marginally higher in the patients receiving GTR (25 Fig. 2 . Upper: Kaplan-Meier curves depicting survival of the 34 patients undergoing primary operation at UCSF. A Cox regression analysis controlling for age and KPS score demonstrated a minor survival benefit for the patients undergoing NTR when compared with GTR (p = 0.035). Lower: Kaplan-Meier curves depicting survival of the 37 patients undergoing a second operation. A Cox regression analysis controlling for age and KPS score demonstrated a minor survival benefit for the patients undergoing NTR when compared with GTR (p = 0.005). STR = subtotal resection (referred to as NTR in text). vs 11%; p = 0.19, chi-square test); however this difference represented only a weak statistical trend.
Discussion
Due to the relative infrequency of malignant meningiomas, 14 there are few clinical data in the modern neurosurgical era that demonstrate the impact of multimodality therapy in which newer technologies, such as image-guided surgical systems, intensity-modulated radiotherapy, and radiosurgery are used. It has long been known that atypical and malignant meningiomas often recur, and to prevent this it has been our practice to treat these lesions with postoperative fractionated radiotherapy 1, 18 following the initial surgery. However, the benefits of resection for recurrence have not been clearly demonstrated when compared with repeat irradiation with newer techniques. In addition, no study to date has provided long-term outcomes following resection in a group of malignant meningiomas in patients undergoing both initial and repeat surgery for recurrence. In this study, we provide a large clinical series with comprehensive analysis of patient outcomes and factors affecting survival, which may be compared with older, smaller series.
The suggested benefit of a smaller extent of resection observed in our Kaplan-Meier analysis should be interpreted with caution, because the idea is counterintuitive to our understanding of tumor biology, the relative effect size is fairly modest (note that the Kaplan-Meier survival plots approach each other at later follow-up periods), and we lack as yet an appropriate explanation for this effect, despite our numerous attempts to address potential confounding variables. It should be noted that all subtotal (which we call near-total) resections removed > 90% of tumor, with inoperable portions being confined to areas of great surgical morbidity, such as the motor strip, within the cavernous sinus, or encasement of the internal carotid artery. Thus, these analyses are in fact determining the survival effect of removing the last 1-5% of the tumor, compared with leaving this residual tumor (that is, NTR). We believe it is safe to conclude that heroic efforts to remove the last small portions of tumor probably do not yield impressive improvements in survival. In all likelihood, these patients probably survive as long as patients undergoing NTR. Additionally, it seems that aggressive removal of malignant meningiomas is associated with greater risk of neurological morbidity, regardless of extent of resection, than in lower-grade meningiomas (Table  5) . 19 Furthermore, many of our worst complications with these cases occurred in patients who underwent GTR. Although there is little doubt of the desirability of GTR in cases in which there is a clear plane between the tumor and normal brain, nerves, or vessels, often such a plane does not exist with these tumors. Thus, probably the best overall interpretation of these data is that overly aggressive attempts at GTR in cases without a clear plane of resection do not seem to be significantly beneficial in these patients, and may be harmful in some cases.
Another interesting finding in this study was the beneficial effect of repeat surgery and interstitial brachytherapy for recurrent lesions. Although they did not live as long as patients undergoing a first surgery, patients undergoing a repeat surgery lived almost 5 years, which was 3 years longer than those who did not undergo surgery for their first recurrence. The patients who did not undergo 2 surgeries were older than those who did, and this was probably the reason these patients did not receive surgery for their recurrent tumor. Despite this, the survival benefit of repeat surgery remained prominent even when Cox regression analysis was used to correct these findings for age and KPS score at the time of the first recurrence, suggesting that surgery for recurrent tumors is an effective treatment in appropriate circumstances. Additionally, patients undergoing repeat surgery did not experience an increase in complication rates compared with patients undergoing initial operations, despite having previously been treated with radiation prior to the second surgery. This further emphasizes the value of repeat surgery for these lesions. Tumor location did not seem to affect outcomes in our cohort. Most notably, patients with skull base tumors, which are typically thought to be more challenging and to entail more morbidity when removed, 12, 21 did not seem to have higher complication rates or worse outcomes than patients who had convexity or falcine tumors. One possible explanation for this is that the relative lack of benefit for GTR over NTR with these tumors neutralizes the inherent difficulty of removing skull base tumors completely when compared with convexity meningiomas.
One issue left unresolved by our work is the role of additional focal radiotherapy after surgery for first recurrence. Our analysis found that patients receiving either SRS or permanent 125 I brachytherapy implants fared no better than those who did not. These data could be interpreted 2 different ways. First, an obvious potential confounder is selection bias, in that patients with worse performance status were more likely to receive SRS, as opposed to a third operation, and this might blunt the effect of additional radiotherapy. Also, patients with more aggressive tumors were more likely to have increased interest in brachytherapy at the time of their second surgery. In this interpretation, the fact that patients with multiple worrisome recurrences did not do worse suggests that radiosurgery has some effect in these patients with more clinically aggressive tumors.
An alternate explanation is that these tumors had all received EBRT after the first surgery, and thus the recurrent lesions might be more radioresistant, reducing the clinical benefit of additional radiation. Previous studies have demonstrated poor response of malignant meningiomas to SRS, with all lesions in a series of 8 progressing 4-7 months after initiation of therapy. 15 Similar results were found for a Gamma Knife surgery study in 2001, in which a 40% 5-year overall survival and a 24% 5-year progression-free survival were found following SRS for recurrent lesions. 20 These variables cannot be controlled for in a retrospective cohort, and additional prospective work is needed to address this issue.
Finally, the principal finding of this study is the formal demonstration that surgery with adjuvant radiotherapy is an effective treatment for WHO Grade III meningiomas, with a 10-year survival rate of 40% for patients undergoing initial surgery. These outcomes compare favorably with those in many other patients with high-grade intracranial neoplasms, for whom the prognosis, even with aggressive resection, is far more grim. 13, 16 At our institution, the mean number of procedures (open surgery, radiosurgery) for patients with primary surgery and a diagnosis of malignant meningioma was 2.8. Clearly the bias here is to be aggressive with surgical and radiosurgical methods, because the success rate when using chemotherapy agents such as hydroxyurea and adriamycin/dacar bazine has been determined to be modest at best. Other newer agents, such as irinotecan and temozolomide, were deemed to have the potential to prevent recurrence, but failed in recent studies. [6] [7] [8] 10 Therefore, at this time, the use of these agents should be reserved for patients who have documented recurrence and are not surgical candidates, and whose lesion is unresponsive to radiation. Based on the findings in this study, surgery is an effective therapy, even for recurrent tumors, and should be considered an option for all patients able to undergo an operation.
Conclusions
It should be acknowledged that this is a retrospective study, and therefore is subject to the typical limitations of all such studies. Most notably, many of the patients underwent a large number of treatments for their tumor, and some underwent the same procedure multiple times, with underlying treatment rationales that are not always entirely clear from the records. It is therefore very difficult, even in a series this size, to determine the survival benefit of any particular therapy precisely while controlling for the effects of other concomitant or subsequent therapies. Thus, until larger bodies of prospectively collected data are available, these data would best be viewed as estimates of the expected outcome following surgery with appropriately aggressive multimodality therapy of the type provided at a center specializing in the care of patients with meningioma. With that said, this is the largest series in the literature demonstrating long-term outcomes with WHO Grade III meningiomas, and it provides useful estimates of expected outcomes with this treatment in lieu of Class I data.
